Safety and Efficacy of Treatment with/without Ramucirumab in Advanced or Metastatic Cancer: A Meta-Analysis of 11 Global, Double-Blind, Phase 3 Randomized Controlled Trials

Ramucirumab, as a vascular endothelial growth factor receptor-2 inhibitor, was first approved in 2014 for treated advanced or metastatic gastric/gastroesophageal junction (GEJ) adenocarcinoma. This study deeply analyzed the efficacy and safety of advanced or metastatic cancer treated with ramuciruma...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Lingxue, Wang, Tong, Zhang, Qianqian, Yu, Sheng, Li, Wen, Yao, Senbang, Cheng, Huaidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9705087/
https://www.ncbi.nlm.nih.gov/pubmed/36451771
http://dx.doi.org/10.1155/2022/2476469

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9705087/
https://www.ncbi.nlm.nih.gov/pubmed/36451771
http://dx.doi.org/10.1155/2022/2476469

Ejemplares similares